Cargando…

Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program

AIMS/INTRODUCTION: Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register. MATERIALS AND METHODS: We carried out a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gani, Linsey, Lau, Eric, Luk, Andrea, Sobrepena, Leorino, Tran, Quang Khanh, Kesavadev, Jothydev, Jia, Weiping, Yu, Weinan, Tsang, Chiu Chi, Mukhopadhyay, Monojitketan, Jha, Sujeet, Sheu, Wayne, Ho, Yoon Kun, Nguyen, Thy Khue, Ozaki, Risa, So, Wing Yee, Kwan, Christine, Fu, Amy W C, Mirasol, Roberto, Phatak, Sanjeev Ratnakar, Kumar, Kanakatte Mylariah Prasanna, Aravind, Sosale, Janakiraman, Hari, Chan, Juliana C N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215931/
https://www.ncbi.nlm.nih.gov/pubmed/29575724
http://dx.doi.org/10.1111/jdi.12843
_version_ 1783368238279688192
author Gani, Linsey
Lau, Eric
Luk, Andrea
Sobrepena, Leorino
Tran, Quang Khanh
Kesavadev, Jothydev
Jia, Weiping
Yu, Weinan
Tsang, Chiu Chi
Mukhopadhyay, Monojitketan
Jha, Sujeet
Sheu, Wayne
Ho, Yoon Kun
Nguyen, Thy Khue
Ozaki, Risa
So, Wing Yee
Kwan, Christine
Fu, Amy W C
Mirasol, Roberto
Phatak, Sanjeev Ratnakar
Kumar, Kanakatte Mylariah Prasanna
Aravind, Sosale
Janakiraman, Hari
Chan, Juliana C N
author_facet Gani, Linsey
Lau, Eric
Luk, Andrea
Sobrepena, Leorino
Tran, Quang Khanh
Kesavadev, Jothydev
Jia, Weiping
Yu, Weinan
Tsang, Chiu Chi
Mukhopadhyay, Monojitketan
Jha, Sujeet
Sheu, Wayne
Ho, Yoon Kun
Nguyen, Thy Khue
Ozaki, Risa
So, Wing Yee
Kwan, Christine
Fu, Amy W C
Mirasol, Roberto
Phatak, Sanjeev Ratnakar
Kumar, Kanakatte Mylariah Prasanna
Aravind, Sosale
Janakiraman, Hari
Chan, Juliana C N
author_sort Gani, Linsey
collection PubMed
description AIMS/INTRODUCTION: Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register. MATERIALS AND METHODS: We carried out a cross‐sectional analysis in 81,531 patients with type 1 and type 2 diabetes enrolled into the Joint Asia Diabetes Evaluation Program from 2007 to 2014. All insulin related terms are extracted from the Joint Asia Diabetes Evaluation portal, and compared clinical profiles between biosimilar and originator insulin users. Multivariate analysis was performed to assess the association of biosimilar insulin compared with originator insulin with dosage, glycated hemoglobin and hypoglycemia events. RESULTS: Amongst 81,531 patients, 20.5% (n = 16,738) were insulin‐treated. In four countries with high use of biosimilar insulin, 4.7% (n = 719) of insulin users (n = 10,197) were treated with biosimilar insulin (India n = 507, 70.3%; the Philippines n = 90, 12.5%; China n = 62, 8.6%; Vietnam n = 60, 8.3%). Biosimilar insulin users were younger and had higher body mass index, glycated hemoglobin, insulin dosage and more frequent hypoglycemia than originator insulin users. These associations were non‐significant after adjustment for confounders. Only age, college education, diabetes education, lipid control, physical activity and history of cardiovascular complications were independently associated with these quality measures. CONCLUSIONS: Biosimilar insulin use is not uncommon in Asia. Data exclusion due to incomplete capturing of brand names suggests possibly higher use. The multiple determinants of the quality of glycemic control call for establishment of prospective cohorts and diabetes registers to monitor the safety and efficacy of different brands of biosimilar insulin and their impacts on clinical outcomes.
format Online
Article
Text
id pubmed-6215931
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62159312018-11-08 Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program Gani, Linsey Lau, Eric Luk, Andrea Sobrepena, Leorino Tran, Quang Khanh Kesavadev, Jothydev Jia, Weiping Yu, Weinan Tsang, Chiu Chi Mukhopadhyay, Monojitketan Jha, Sujeet Sheu, Wayne Ho, Yoon Kun Nguyen, Thy Khue Ozaki, Risa So, Wing Yee Kwan, Christine Fu, Amy W C Mirasol, Roberto Phatak, Sanjeev Ratnakar Kumar, Kanakatte Mylariah Prasanna Aravind, Sosale Janakiraman, Hari Chan, Juliana C N J Diabetes Investig Articles AIMS/INTRODUCTION: Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register. MATERIALS AND METHODS: We carried out a cross‐sectional analysis in 81,531 patients with type 1 and type 2 diabetes enrolled into the Joint Asia Diabetes Evaluation Program from 2007 to 2014. All insulin related terms are extracted from the Joint Asia Diabetes Evaluation portal, and compared clinical profiles between biosimilar and originator insulin users. Multivariate analysis was performed to assess the association of biosimilar insulin compared with originator insulin with dosage, glycated hemoglobin and hypoglycemia events. RESULTS: Amongst 81,531 patients, 20.5% (n = 16,738) were insulin‐treated. In four countries with high use of biosimilar insulin, 4.7% (n = 719) of insulin users (n = 10,197) were treated with biosimilar insulin (India n = 507, 70.3%; the Philippines n = 90, 12.5%; China n = 62, 8.6%; Vietnam n = 60, 8.3%). Biosimilar insulin users were younger and had higher body mass index, glycated hemoglobin, insulin dosage and more frequent hypoglycemia than originator insulin users. These associations were non‐significant after adjustment for confounders. Only age, college education, diabetes education, lipid control, physical activity and history of cardiovascular complications were independently associated with these quality measures. CONCLUSIONS: Biosimilar insulin use is not uncommon in Asia. Data exclusion due to incomplete capturing of brand names suggests possibly higher use. The multiple determinants of the quality of glycemic control call for establishment of prospective cohorts and diabetes registers to monitor the safety and efficacy of different brands of biosimilar insulin and their impacts on clinical outcomes. John Wiley and Sons Inc. 2018-04-24 2018-11 /pmc/articles/PMC6215931/ /pubmed/29575724 http://dx.doi.org/10.1111/jdi.12843 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Gani, Linsey
Lau, Eric
Luk, Andrea
Sobrepena, Leorino
Tran, Quang Khanh
Kesavadev, Jothydev
Jia, Weiping
Yu, Weinan
Tsang, Chiu Chi
Mukhopadhyay, Monojitketan
Jha, Sujeet
Sheu, Wayne
Ho, Yoon Kun
Nguyen, Thy Khue
Ozaki, Risa
So, Wing Yee
Kwan, Christine
Fu, Amy W C
Mirasol, Roberto
Phatak, Sanjeev Ratnakar
Kumar, Kanakatte Mylariah Prasanna
Aravind, Sosale
Janakiraman, Hari
Chan, Juliana C N
Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
title Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
title_full Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
title_fullStr Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
title_full_unstemmed Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
title_short Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
title_sort cross‐sectional survey of biosimilar insulin utilization in asia: the joint asia diabetes evaluation program
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215931/
https://www.ncbi.nlm.nih.gov/pubmed/29575724
http://dx.doi.org/10.1111/jdi.12843
work_keys_str_mv AT ganilinsey crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT laueric crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT lukandrea crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT sobrepenaleorino crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT tranquangkhanh crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT kesavadevjothydev crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT jiaweiping crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT yuweinan crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT tsangchiuchi crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT mukhopadhyaymonojitketan crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT jhasujeet crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT sheuwayne crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT hoyoonkun crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT nguyenthykhue crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT ozakirisa crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT sowingyee crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT kwanchristine crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT fuamywc crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT mirasolroberto crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT phataksanjeevratnakar crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT kumarkanakattemylariahprasanna crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT aravindsosale crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT janakiramanhari crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT chanjulianacn crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram
AT crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram